Bosentan, a dual endothelin receptor blocker, has been used clinically to treat idiopathic pulmonary arterial hypertension (IPAH). However, the mechanism of its antiproliferative effect on pulmonary artery smooth muscle cells (PASMCs) Idiopathic pulmonary arterial hypertension (IPAH), formerly referred to as primary pulmonary hypertension, is a progressive and fatal disease that predominantly affects women. Although the pathogenesis and etiology of IPAH remain unclear, pulmonary vascular remodeling (characterized by vascular intimal and medial hypertrophy) is the major cause for the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with IPAH (1, 2). Pulmonary vascular medial hypertrophy is caused mainly by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs). The search for the cause of the inappropriate PASMC proliferation in IPAH has yielded a heterogeneous spectrum of derangements including elevation of circulating mitogens (3-6), dysfunction of growth factor receptors (7-9), and abnormality of ion channels (10).
Idiopathic pulmonary arterial hypertension (IPAH), formerly referred to as primary pulmonary hypertension, is a progressive and fatal disease that predominantly affects women. Although the pathogenesis and etiology of IPAH remain unclear, pulmonary vascular remodeling (characterized by vascular intimal and medial hypertrophy) is the major cause for the elevated pulmonary vascular resistance and pulmonary arterial pressure in patients with IPAH (1, 2) . Pulmonary vascular medial hypertrophy is caused mainly by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs). The search for the cause of the inappropriate PASMC proliferation in IPAH has yielded a heterogeneous spectrum of derangements including elevation of circulating mitogens (3) (4) (5) (6) , dysfunction of growth factor receptors (7) (8) (9) , and abnormality of ion channels (10) .
A rise in cytoplasmic Ca 2ϩ concentration ([Ca 2ϩ ] cyt ) in PASMCs is an important stimulus for PASMC proliferation (11, 12) . [Ca 2ϩ ] cyt can be increased in PASMCs by Ca 2ϩ release from the sarcoplasmic or endoplasmic reticulum and by Ca 2ϩ influx from extracellular sites to the cytosol via Ca 2ϩ channels in the (Received in original form December 8, 2003 ; accepted in final form August 16, 2004) Supported by the National Heart, Lung, and Blood Institute (National Institutes of Health grants HL 66012, HL 64945, HL 54043, and HL 66941).
plasma membrane. In human PASMCs, there are three classes of Ca 2ϩ channels: voltage-dependent, receptor-operated, and storeoperated Ca 2ϩ channels (13) (14) (15) (16) (17) . Receptor-and store-operated Ca 2ϩ channels are important Ca 2ϩ entry pathways in PASMCs, especially on activation of membrane receptors for growth factors and mitogenic agonists (14) (15) (16) (17) (18) . The transient receptor potential (TRP) channel genes have been demonstrated to encode subunits that form functional receptor-and store-operated Ca 2ϩ channels (17) . In animal and human PASMCs, canonical TRP (TRPC) channels are involved in agonist-mediated pulmonary vasoconstriction (14) and mitogen-mediated cell proliferation (11, 12) .
Endothelin-1 is a potent pulmonary vasoconstrictor and PASMC mitogen (3) (4) (5) (6) (18) (19) (20) (21) (22) . Its mechanism of action involves binding to endothelin receptors with the subsequent activation of phospholipase C, which causes hydrolysis of phosphatidylinositol and generation of cytosolic inositol trisphosphate and membrane-bound diacylglycerol. Inositol trisphosphate causes a rapid Ca 2ϩ increase followed by a sustained Ca 2ϩ influx to induce contraction. Diacylglycerol activates protein kinase C and triggers intracellular mechanisms that promote cell proliferation and migration through the mitogen-activated protein kinase cascade (21) . Enhanced local production of endothelin-1 by pulmonary vascular endothelial cells correlates with the severity of pulmonary vascular remodeling, suggesting a causal role for endothelin-1 in the development of pulmonary arterial hypertension (3, 5, 22) .
Bosentan, a potent antagonist of endothelin receptors, is an orally administered drug approved by the Food and Drug Administration for the treatment of pulmonary arterial hypertension. Randomized clinical trial studies show that treatment with bosentan significantly increased cardiac index, reduced pulmonary vascular resistance, decreased mean pulmonary arterial pressure, and increased exercise capacity in patients with severe pulmonary arterial hypertension (23) (24) (25) . However, little is known about its in vitro mechanism of action. This study was designed to test the hypothesis that endothelin-1-mediated PASMC proliferation involves the upregulation of TRPC channel expression, and the therapeutic effect of bosentan is due partially to its downregulatory effect on TRPC channels. To test the specificity of the antiproliferative effects of bosentan, we also examined whether bosentan affected PASMC proliferation mediated by platelet-derived growth factor (PDGF), a mitogen that works independent of endothelin receptors. Some of the results of these studies have been previously reported in the form of an abstract (26) .
METHODS

Cell Preparation and Culture
Human PASMCs from normal subjects were purchased from Cambrex Bio Science (Walkersville, MD) and used at Passage 4-6. The cells were cultured at 37ЊC in smooth muscle growth medium (SMGM), which is composed of smooth muscle basal medium (SMBM), 5% fetal bovine serum (FBS), human epidermal growth factor (0.5 ng/ ml), human fibroblast growth factor (2 ng/ml), and insulin (5 g/ml). PASMCs from transplant patients were used in some experiments (10).
There were two patients with IPAH from whom lung tissues were obtained to prepare PASMCs for the study. The diagnosis of IPAH was established clinically in these patients on the basis of the criteria used in the National Institutes of Health Registry on Primary Pulmonary Hypertension and was confirmed histopathologically. The mean pulmonary arterial pressure of the two patients with IPAH (a 57-year-old white woman and a 32-year-old white man) was 66 and 53 mm Hg, respectively. Both of the patients with IPAH had been treated with epoprostenol (Flolan), warfarin, digoxin, and furosemide before lung transplantation. The patients from whom we obtained lung tissues for preparing PASMCs gave written informed consent: all protocols were approved by the Institutional Review Board of the University of California, San Diego (La Jolla, CA). Lung tissues, removed from patients in the operating room, were immediately placed in cold (4ЊC) saline and taken to the laboratory for dissection. Muscular pulmonary arteries were incubated in Hanks' balanced salt solution containing collagenase (2 mg/ml; Worthington Biochemical, Lakewood, NJ) for 20 minutes. The adventitia was stripped, and the endothelium was removed. The remaining smooth muscle was digested with collagenase (2.25 mg/ml), elastase (0.5 mg/ml), and albumin (1 mg/ml) (Sigma, St. Louis, MO) at 37ЊC to make a cell suspension of PASMCs. The cells were resuspended and then incubated in SMGM at 37ЊC.
Rat PASMCs were isolated from intrapulmonary arteries (Division 3 or 4) of male Sprague-Dawley rats (125-250 g) and cultured at 37ЊC in Dulbecco's modified Eagle's medium (DMEM) containing FBS (10%), penicillin (100 U/ml) and streptomycin (100 mg/ml). The cells were passaged by trypsinization with 0.05% trypsin-EDTA and used for experiments at passages 3-6 (12, 27) .
Determination of Cell Growth
Cell number was determined with a hemocytometer. Cell counts in the four 1-mm 3 corner squares of the hemocytometer were averaged to calculate total cell number per milliliter of cell suspension. Cell number, normalized by the size of the petri dishes (cells per centimeter squared), was used to compare cell growth rate. Cell viability was determined with 0.45% trypan blue (Sigma). 
Western Blot Analysis
Cells were gently washed twice in cold phosphate-buffered saline, scraped into 0.3 ml of lysis buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, phenylmethylsulfonyl fluoride [100 g/ml], and aprotinin [30 l/ml]), and incubated for 30 minutes on ice. The cell lysates were then sonicated and centrifuged at 12,000 rpm for 10 minutes, and the insoluble fraction was discarded. The protein concentration in the supernatant was determined by the bicinchoninic acid protein assay, using bovine serum albumin as a standard. Ten to 25 g of proteins was mixed and boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer for 5 minutes. The protein samples separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis were then transferred to nitrocellulose membranes by electroblotting in a Mini Trans-Blot cell transfer apparatus according to the manufacturer's instructions (Bio-Rad, Hercules, CA). After incubation overnight at 4ЊC in a blocking buffer (0.1% Tween 20 in phosphate-buffered saline) containing 5% nonfat dry milk powder, the membranes were incubated with anti-actin monoclonal antibody (Sigma) and anti-TRPC6 polyclonal antibody (Alomone Labs, Jerusalem, Israel). The membranes were then washed and incubated with anti-rabbit or anti-mouse horseradish peroxidase-conjugated IgG for 90 minutes at room temperature. The bound antibody was detected with an enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ).
Statistical Analysis
Data are expressed as means Ϯ SD. Statistical analysis was performed by paired or unpaired Student t test, or by analysis of variance and post hoc tests (Student-Newman-Keuls) as indicated. Differences are considered to be significant when p Ͻ 0.05.
RESULTS
Bosentan Inhibits Endothelin-1-mediated Human PASMC Proliferation
The mitogenic effect of endothelin was first examined in human PASMCs cultured in low-serum (1% FBS) medium. Endothelin-1 at concentrations of 10 Ϫ7 and 10 Ϫ6 M (for 48 hours) significantly increased cell number (by 22 and 31%, respectively) and [ To examine whether bosentan has any toxic effect on human PASMCs, we first incubated PASMCs in medium with or without 50 M bosentan for 48 hours. We then measured the number of cells that were positively stained with 0.45% trypan blue. Of PASMCs incubated in medium without bosentan, the percentage of trypan blue-positive cells was 3.27%, whereas of cells cultured in medium containing 50 M bosentan, the percentage of necrotic cells was 6.05% (p Ͼ 0.1). These results indicate that bosentan has little toxic effect on human PASMCs. 
Bosentan Inhibits PDGF-mediated Human PASMC Proliferation
Increased levels of endothelin-1 and PDGF in lung tissues and blood plasma have been observed in patients and animals with pulmonary arterial hypertension (3) (4) (5) (6) (28) (29) (30) . To investigate whether bosentan interferes with other proliferative mechanisms (e.g., PDGF signaling pathway) in PASMCs, we examined the effect of bosentan on PDGF-mediated PASMC proliferation.
In rat PASMCs, PDGF (10 ng/ml in 0.2% FBS-DMEM, for 48 hours) caused an approximately 3-fold increase in cell number (p Ͻ 0.001). Interestingly, bosentan caused a dose-dependent inhibition of PDGF-mediated rat PASMC growth (Figure 2A) . The PDGF-induced increase in cell number was reduced by 33, 39, and 73%, respectively, in PASMCs treated with 10, 20, and 50 M bosentan. Furthermore, bosentan also significantly inhibited the PDGF-mediated increase in [ 3 H]thymidine uptake (Figure 2A) . The inhibitory effect of bosentan on PASMC growth was also replicated in normal human PASMCs ( Figure 2B ).
Many mechanisms are involved in vascular smooth muscle cell proliferation when cells are stimulated with mitogenic agonists (2, 31) . In PASMCs, we previously reported that inhibition of both TRPC channel expression and function inhibited PASMC proliferation, suggesting an important role for Ca 2ϩ influx through TRPC channels in mediating PASMC growth (11, 12, 27) . The next set of experiments was designed to test whether the antiproliferative effect of bosentan is due to attenuation of TRPC channel expression.
Bosentan Inhibits Endothelin-1-mediated and PDGF-mediated Upregulation of TRPC6 in PASMCs
TRPC6 is a canonical TRP channel isoform highly expressed in lung tissues and vasculature (14) (15) (16) (32) (33) (34) . TRPC6 participates in forming receptor-and store-operated Ca 2ϩ channels that are activated by vasoconstrictive and mitogenic agonists (16) . In human PASMCs, endothelin-1 (10 Ϫ6 M, for 48 hours) significantly increased the protein expression level of TRPC6 ( Figure   Figure 2 . Bosentan inhibits platelet-derived growth factor (PDGF)-mediated pulmonary artery smooth muscle cell (PASMC) proliferation. Summarized data (means Ϯ SD) from rat (A, panel a; n ϭ 9 experiments) and human (B, n ϭ 9 experiments) PASMCs showing cell numbers before (Basal) and 48 hours after incubation in PDGF (10 ng/ml)-containing medium with 0 (solid column), 10, 20, and 50 M bosentan (shaded columns). 3A), whereas bosentan caused a dose-dependent inhibition of endothelin-1-mediated TRPC6 upregulation ( Figure 3A) . Similar to endothelin-1, PDGF also upregulated the protein expression of TRPC6 in human and rat PASMCs, whereas bosentan markedly downregulated TRPC6 expression. Bosentan not only abolished the PDGF-mediated increase in TRPC6 protein expression, but also decreased the protein level of TRPC6 to a level lower than the level in cells treated with vehicle ( Figures  3B and 3C) . These results suggest that (1 ) endothelin-1-mediated and PDGF-mediated PASMC proliferation is associated with upregulation of TRPC6, and (2 ) bosentan-induced TRPC6 downregulation may be an important mechanism by which it inhibits PASMC proliferation.
Effects of Ca 2؉ Channel Blockers on PDGF-mediated TRPC6 Upregulation and PASMC Proliferation
To investigate whether PDGF-mediated TRPC6 upregulation and PASMC proliferation depend on Ca 2ϩ influx through voltagedependent Ca 2ϩ channels (VDCCs) or through receptor-operated Ca 2ϩ channels (ROCs) and store-operated Ca 2ϩ channels (SOCs), we examined the effects of nifedipine (a specific blocker of VDCC) and SKF 96365 (SKF, a selective blocker of ROCs and SOCs) on TRPC6 expression and PASMC growth. As shown in Figure 4A , blockade of VDCCs with nifedipine or of ROCs and SOCs with SKF negligibly affected PDGF-induced TRPC6 upregulation. However, blockade of ROCs and SOCs with SKF markedly inhibited PDGF-induced PASMC proliferation, whereas blockade of VDCCs with nifedipine had little effect ( Figure 4B ). These data indicate that (1 ) PDGF-mediated TRPC6 upregulation is not dependent on Ca 2ϩ influx through either VDCCs or ROCs and SOCs; and (2 ) PDGF-mediated PASMC proliferation is partially dependent on Ca 2ϩ influx through the SKFsensitive ROCs and SOCs. Because TRPC6 is an important subunit that participates in forming functional ROCs and SOCs, bosentan, by downregulating TRPC6 expression, had a similar inhibitory effect on PASMC proliferation in response to SKF ( Figure 4B ).
Bosentan Inhibits PDGF-mediated Phosphorylation of Signal Transducer and Activator of Transcription
On activation of PDGF receptor, a receptor tyrosine kinase, phosphorylation of signal transducer and activator of transcription-3 (STAT3) is an immediate downstream signal transduction step in the cascade of PDGF-mediated cell proliferation. Indeed, PDGF (10 ng/ml) increased the protein level of phosphorylated STAT3 (pSTAT3) in human PASMCs. Bosentan (50 M), however, significantly inhibited PDGF-mediated STAT3 phosphorylation ( Figure 5 ). These results indicate that bosentan, in addition to blockade of endothelin receptors, may also interfere with the kinase activity of PDGF receptors and thus inhibit PDGF-mediated STAT3 phosphorylation.
Bosentan-mediated Antiproliferative Effect Is Enhanced in IPAH-PASMCs
To examine whether the bosentan-mediated antiproliferative effect on PASMCs is different in patients with IPAH, we performed the same experiments using PASMCs from patients with Growth-arrested cells were cultured in SMGM containing various concentrations of bosentan (0, 10, 20, and 50 M) for 48 hours. Normalized increase in cell numbers (means Ϯ SD) by PDGF (10 ng/ml) after treatment with bosentan shows that bosentan-induced inhibition on cell growth is significantly greater than in IPAH-PASMCs (n ϭ 9 experiments) than in normal PASMCs (n ϭ 9 experiments). **p Ͻ 0.01 versus normal PASMCs. Figure 6 , the inhibitory effect of bosentan on PDGF-mediated PASMC growth was much greater in cells from patients with IPAH than in cells from normal subjects. Furthermore, the protein level of TRPC6 was much higher in IPAH-PASMCs than in normal human PASMCs ( Figure 7A ). Incubation of IPAH-PASMCs with bosentan not only decreased the basal level of TRPC6 proteins, but also inhibited PDGFmediated TRPC6 upregulation ( Figures 7B and 7C ). These results indicate that (1 ) upregulation of TRPC channels may play an essential role in PASMC overgrowth in patients with IPAH; (2 ) downregulation of TRPC6 channels is an effective mechanism for bosentan to attenuate overgrowth of IPAH-PASMCs; and (3 ) the TRPC6 channel is an important target in developing therapeutic approaches for IPAH.
IPAH. As shown in
DISCUSSION
Pulmonary vascular wall thickening due to inappropriate PASMC proliferation is a central cause of the elevated pulmonary vascular resistance and arterial pressure in patients with ] cyt , and stimulate cell proliferation. In addition to blockade of endothelin receptors and their downstream signal transduction pathway, bosentan may also directly downregulate TRPC6 expression by repressing the gene transcription or translation and/or interfering with the signaling mechanism (e.g., signal transducer and activator of transcription-3 [STAT3] phosphorylation) required for growth factor-mediated TRPC6 expression. DAG ϭ diacylglycerol; PKC ϭ protein kinase C.
IPAH (1, 2)
. Increased production of mitogenic agonists, such as endothelin-1 and PDGF in the blood plasma and lung tissues, has been linked to the development of pulmonary vascular remodeling regardless of the etiology (1-6, 21) . The medical treatment of IPAH and severe pulmonary arterial hypertension has been revolutionized by the availability of new therapeutic agents. Bosentan, an orally administered endothelin receptor antagonist, has been shown to produce sustained improvements in pulmonary hemodynamics, 6-minute walk, and other measures of clinical outcome in patients with severe pulmonary arterial hypertension (23) (24) (25) .
A rise in [Ca 2ϩ ] cyt serves as a critical signal to promote gene expression and propel cells to go through the cell cycle. Mitogenic stimulation of PASMCs leads to elevated [Ca 2ϩ ] cyt by triggering Ca 2ϩ release from the sarcoplasmic reticulum and Ca 2ϩ influx through receptor-operated Ca 2ϩ channels (ROCs) and store-operated Ca 2ϩ channels (SOCs) (14) (15) (16) (17) (18) (32) (33) (34) (35) (36) (37) (38) . Removal of extracellular Ca 2ϩ and chelation of intracellular Ca 2ϩ significantly inhibit PASMC proliferation in the presence of serum and growth factors (12, 27) , suggesting that a constant Ca 2ϩ influx or a sufficient level of [Ca 2ϩ ] in the cytosol and intracellular organelles is an essential requisite for mitogen-mediated PASMC proliferation.
The canonical transient receptor potential (TRPC) channels are believed to participate in forming functional ROCs and SOCs in many cell types including PASMCs (11, 12, (14) (15) (16) (17) (32) (33) (34) . Indeed, downregulation of TRPC channels (e.g., TRPC1 and TRPC6) with antisense oligonucleotides inhibits receptor-mediated Ca 2ϩ influx (16) and efficiently attenuates PASMC proliferation (11, 12, 27) . It has been demonstrated that endothelin receptors are actually colocalized with TRPC channels in caveolae (15) ; therefore, TRPC channels serve as a critical effecter for the endothelin receptor in endothelin-mediated vasoconstrictive and mitogenic effect on vascular smooth muscle cells.
The data from this study show that bosentan, as a nonselective blocker of endothelin receptors (ET A and ET B ), not only inhibits endothelin-1-mediated PASMC proliferation, but also attenuates PDGF-mediated PASMC proliferation (Figure 8 ). The antiproliferative effect of bosentan results, at least in part, from its downregulating effect on the TRPC6 channel, a TRPC channel subunit that forms function ROCs (16) and SOCs (12) . Taken together, these data suggest that, in addition to blockade of endothelin receptors, downregulation of TRPC6 channel expression is another important mechanism by which bosentan inhibits PASMC proliferation. How bosentan decreases TRPC6 protein expression in PASMCs remains unclear; interference with STAT3 phosphorylation seems to be a potential mechanism by which bosentan inhibits PDGF-mediated TRPC6 upregulation. Given the fact that bosentan also inhibits inflammatory reactions and prevents development of fibrosis in animals with pulmonary inflammation (39) as well as other diseases (21), it is fair to speculate that the therapeutic action of bosentan may involve multiple targets and downstream signaling pathways that lead to the progression of pulmonary vascular remodeling in patients with IPAH.
In PASMCs from patients with IPAH, our data show that the protein expression level of TRPC6 channels is much higher than in PASMCs from normal subjects. Interestingly, the antiproliferative effect of bosentan is also greater in IPAH-PASMCs than in normal PASMCs; this may be due to the abnormally upregulated TRPC6 in PASMCs from patients with IPAH. It must be emphasized that this study is limited to PASMCs from a limited number of patients, with no data allowing for pathological, hemodynamic, or clinical correlations.
TRPC6 is highly expressed in the lung and vascular smooth muscles relative to other organs (e.g., heart and kidney) and tissue types (32, 33) , suggesting that TRPC6 is a critical Ca 2ϩ channel involved in regulating [Ca 2ϩ ] cyt in pulmonary vascular smooth muscle and endothelial cells (40, 41) . Indeed, inhibition of TRPC6 channel expression with antisense oligonucleotides attenuates, whereas overexpression of TRPC6 channels enhances, agonist-or mitogen-mediated increases in [Ca 2ϩ ] cyt (16) as well as store depletion-mediated increases in [Ca 2ϩ ] cyt (12) . These data suggest that whether the TRPC6 channel is a ROC or SOC may depend on its distribution (i.e., cell or tissue specific), and on the type of TRPC isoforms with which it forms heterotetramers (17, 42) . Regardless of whether it forms either a ROC or SOC, TRPC6 is a critical Ca 2ϩ -permeable channel in regulating [Ca 2ϩ ] cyt ; its function and expression may play a critical role in PASMC proliferation. Overexpression of TRPC6 channels may contribute to the development or progression of pulmonary vascular remodeling in patients with IPAH. Drugs that specifically inhibit TRPC6 channel function and expression would enhance the efficacy of treatment of these patients (especially those who do not respond to conventional Ca 2ϩ channel blockers and vasodilators).
Pulmonary vascular remodeling is caused by a heterogeneous constellation of genetic derangements, which ultimately give rise to a common pathologic event, PASMC overgrowth (1). These derangements can be broadly classified on the basis of the mechanisms of action. For example, mutations of the bone morphogenetic protein receptor Type II gene (BMPR2) are ultimately linked to increased PASMC proliferation and decreased PASMC apoptosis (7-9), whereas enhanced angiopoietin-1 expression is associated, via pulmonary vascular endothelial cells, with elevated levels of serotonin, a potent vasoconstrictor and mitogen (43, 44) . At present, we do not know whether the proliferative effect of angiopoietin-1 and the proapoptotic or antiproliferative effect of bone morphogenetic proteins directly involve regulation of TRPC6 channel expression and function. Nevertheless, it is plausible that TRPC6 or other TRPC channels serve as a downstream effecter in mediating PASMC proliferation in patients with IPAH who have mutant BMPR2 and overexpressed angiopoietin-1.
In summary, bosentan potently inhibits mitogen-mediated PASMC growth. The bosentan-induced antiproliferative effect on normal and IPAH-PASMCs is, at least in part, due to downregulation of TRPC6 protein expression. These observations raise the hypothesis that the antiproliferative effect of bosentan on PASMCs involves the downregulation of TRPC6 channels, possibly independent of endothelin receptor blockade. These findings suggest that inhibition of TRPC protein expression in PASMCs is an efficacious downstream target in the development of new therapeutic approaches for the treatment of pulmonary arterial hypertension.
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